Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 78, Issue 4, pp 809–814 | Cite as

Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer

  • Takeshi Kawakami
  • Nozomu Machida
  • Hirofumi Yasui
  • Masahiro Kawahira
  • Sadayuki Kawai
  • Yosuke Kito
  • Yukio Yoshida
  • Satoshi Hamauchi
  • Takahiro Tsushima
  • Akiko Todaka
  • Tomoya Yokota
  • Kentaro Yamazaki
  • Akira Fukutomi
  • Yusuke Onozawa
Original Article

Abstract

Purpose

Although irinotecan monotherapy is often used in third-line treatment after the failure of taxanes in Japanese clinical practice, its survival benefit is still unclear. The aim of this study is to investigate the efficacy and safety of irinotecan monotherapy as third-line treatment.

Methods

Clinical data from consecutive patients in whom irinotecan had been initiated as third-line treatment between December 2003 and July 2015 in Shizuoka Cancer Center were retrospectively analyzed. Patients who were refractory or intolerant to fluoropyrimidine with or without platinum in first-line treatment and subsequent therapy with taxanes were included in this study. Irinotecan was administered at 150 mg/m2 every 2 weeks.

Results

The data of 50 patients who met the inclusion criteria were analyzed. The overall response rate was 18.4 % (7/38) among the patients with measurable disease. The median progression-free survival time was 66 days, and the median survival time was 180 days from the initiation of irinotecan therapy. The major grade 3 or 4 adverse events including neutropenia, fatigue, and anorexia were observed in 12 (24 %), 8 (16 %), and 7 (14 %), respectively. No treatment-related deaths occurred. Thirteen patients (26 %) required a dose reduction to 120 mg/m2 or less from the initiation of irinotecan.

Conclusions

This study suggests that irinotecan as third-line treatment has an anti-tumor effect and is feasible with optimal dose modification for advanced gastric cancer.

Keywords

Advanced gastric cancer Irinotecan Third-line treatment Salvage line 

Notes

Acknowledgments

The authors thank the patients and their families for their participation in this study.

Compliance with ethical standards

Conflict of interest

The authors have no potential conflicts of interest.

References

  1. 1.
    Ferlay J SI, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International agency for research on Cancer; 2013. http://globocan.iarc.fr (accessed Oct 7, 2015)
  2. 2.
    Statistics and Information Department MoH, Labour and Welfare. Vital statistics in 2014 (in Japanese). http://www.mhlwgojp/Accessed 1 Nov 2015
  3. 3.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221. doi: 10.1016/s1470-2045(08)70035-4 CrossRefPubMedGoogle Scholar
  4. 4.
    Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069. doi: 10.1016/s1470-2045(09)70259-1 CrossRefPubMedGoogle Scholar
  5. 5.
    Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306–2314. doi: 10.1016/j.ejca.2011.06.002 CrossRefPubMedGoogle Scholar
  6. 6.
    Kang JH, Lee SI, Lim do H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513–1518. doi: 10.1200/jco.2011.39.4585 CrossRefPubMedGoogle Scholar
  7. 7.
    Ford HE, Marshall A, Bridgewater JA et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15:78–86. doi: 10.1016/s1470-2045(13)70549-7 CrossRefPubMedGoogle Scholar
  8. 8.
    Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39. doi: 10.1016/s0140-6736(13)61719-5 CrossRefPubMedGoogle Scholar
  9. 9.
    Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438–4444. doi: 10.1200/jco.2012.48.5805 CrossRefPubMedGoogle Scholar
  10. 10.
    Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235. doi: 10.1016/s1470-2045(14)70420-6 CrossRefPubMedGoogle Scholar
  11. 11.
    NCCN Clinical Practice Guidelines in Oncology Gastric Cancer v.3 2015, accessed Nov 9, 2015, at http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
  12. 12.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi: 10.1016/j.ejca.2008.10.026 CrossRefPubMedGoogle Scholar
  13. 13.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. doi: 10.1038/bmt.2012.244 CrossRefPubMedGoogle Scholar
  14. 14.
    Shimoyama R, Yasui H, Boku N et al (2009) Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer 12:206–211. doi: 10.1007/s10120-009-0524-9 CrossRefPubMedGoogle Scholar
  15. 15.
    Li J, Qin S, Xu J et al (2016) Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol 34:1448–1454. doi: 10.1200/jco.2015.63.5995 CrossRefPubMedGoogle Scholar
  16. 16.
    Kang EJ, Im SA, Oh DY et al (2013) Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer 16:581–589. doi: 10.1007/s10120-012-0227-5 CrossRefPubMedGoogle Scholar
  17. 17.
    Higuchi K, Tanabe S, Shimada K et al (2014) Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer 50:1437–1445. doi: 10.1016/j.ejca.2014.01.020 CrossRefPubMedGoogle Scholar
  18. 18.
    Nishikawa K, Fujitani K, Inagaki H et al (2015) Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer 51:808–816. doi: 10.1016/j.ejca.2015.02.009 CrossRefPubMedGoogle Scholar
  19. 19.
    Ohtsu A, Ajani JA, Bai YX et al (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31:3935–3943. doi: 10.1200/jco.2012.48.3552 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Takeshi Kawakami
    • 1
  • Nozomu Machida
    • 1
  • Hirofumi Yasui
    • 1
  • Masahiro Kawahira
    • 1
  • Sadayuki Kawai
    • 1
  • Yosuke Kito
    • 1
  • Yukio Yoshida
    • 1
  • Satoshi Hamauchi
    • 1
  • Takahiro Tsushima
    • 1
  • Akiko Todaka
    • 1
  • Tomoya Yokota
    • 1
  • Kentaro Yamazaki
    • 1
  • Akira Fukutomi
    • 1
  • Yusuke Onozawa
    • 2
  1. 1.Department of Gastrointestinal OncologyShizuoka Cancer CenterNagizumi-ChoJapan
  2. 2.Department of Clinical OncologyShizuoka Cancer CenterShizuokaJapan

Personalised recommendations